Zobrazeno 1 - 10
of 176
pro vyhledávání: '"Wendy B. London"'
Autor:
Florette K. Hazard, Wendy B. London, Hiroyuki Shimada, Arlene Naranjo, Michael D. Hogarty, Bill Chiu, Julie M. Gastier-Foster, Brian LaBarre, Naohiko Ikegaki, Julie R. Park, Susan L. Cohn, John M. Maris, Asuka Kawano
Publikováno v:
American Journal of Surgical Pathology. 45:1075-1081
Stage 4S neuroblastoma (4SNB) is associated with spontaneous tumor regression and an excellent prognosis. However, a small group of the patients have a poor prognosis. One hundred eighty-five stage 4SNB cases filed at the Children's Oncology Group Ne
Autor:
Steven G. DuBois, Stephan A. Grupp, John J. Doski, Daphne A. Haas-Kogan, Julie R. Park, Lisa Diller, Geetika Khanna, Steve Braunstein, Susan G. Kreissman, Wendy B. London, Stephan D. Voss, Arlene Naranjo, Kevin X. Liu, Fan F Zhang, James D. Geiger
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 24
J Clin Oncol
J Clin Oncol
PURPOSE A primary objective of the Children’s Oncology Group (COG) ANBL0532 phase III study was to assess the effect of increasing local dose of radiation to a residual primary tumor on the cumulative incidence of local progression (CILP) in patien
Autor:
Rajen Mody, Barry L. Shulkin, Mildred Felder, Paul M. Sondel, Howard M. Katzenstein, Wendy B. London, Shahab Asgharzadeh, Alice L. Yu, Julia Glade-Bender, Rochelle Bagatell, Marguerite T. Parisi, Arlene Naranjo, Jennifer Birstler, Fan F Zhang, Mitchell B. Diccianni, Jacquelyn A. Hank, Julie R. Park, Sabah-E-Noor Servaes, John M. Maris
Publikováno v:
J Clin Oncol
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 19
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 19
PURPOSE The combination of irinotecan, temozolomide, dintuximab, and granulocyte-macrophage colony-stimulating factor (I/T/DIN/GM-CSF) demonstrated activity in patients with relapsed/refractory neuroblastoma in the randomized Children’s Oncology Gr
Autor:
Wendy B. London, Samuel L. Volchenboum, Arlene Naranjo, Susan L. Cohn, Dominique Valteau-Couanet, Julie R. Park, Andrew D.J. Pearson, Meredith S. Irwin, Michael D. Hogarty, Elizabeth A. Sokol, Gudrun Schleiermacher, Mark A. Applebaum, Ami V. Desai
Publikováno v:
J Clin Oncol
PURPOSE The Children’s Oncology Group (COG) stratifies the treatment of patients with neuroblastoma on the basis of a combination of biomarkers that include age and tumor histology classified by age-linked International Neuroblastoma Pathology Clas
Autor:
Natia Esiashvili, Edward F. Attiyeh, Peter Mattei, Susan L. Cohn, Wendy B. London, Arlene Naranjo, Araz Marachelian, Sheena C. Tenney, Mary Lou Schmidt, John M. Maris, E. Stanton Adkins, Katherine K. Matthay, Julie M. Gastier-Foster, Howard M. Katzenstein, Margaret H. Collins, Clare J. Twist, Julie R. Park, Michael H. Handler, Hiroyuki Shimada, Elizabeth Wagner, Michael D. Hogarty
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 37, iss 34
J Clin Oncol
J Clin Oncol
PURPOSE The primary objective of the Children’s Oncology Group study ANBL0531 (ClinicalTrials.gov identifier: NCT00499616 ) was to reduce therapy for subsets of patients with intermediate-risk neuroblastoma using a biology- and response-based algor
Autor:
Wendy B. London, Barry L. Shulkin, Arlene Naranjo, John M. Maris, Steven D. Gillies, Julie R. Park, Hank Ja, Marguerite T. Parisi, Paul M. Sondel, Sabah Servaes, Collin Van Ryn, Jacek Gan, Suzanne Shusterman, Hiroyuki Shimada
Publikováno v:
Clinical Cancer Research. 25:6044-6051
Purpose: Combining anti-GD2 (disialoganglioside) mAb with GM-CSF, IL2, and isotretinoin is now FDA-approved for high-risk neuroblastoma minimal residual disease (MRD) therapy. The humanized anti-GD2 antibody conjugated to IL2 (hu14.18-IL2) has clinic
Autor:
Holly J. Meany, Cody J. Peer, William D. Figg, Wendy B. London, Suzanne Shusterman, Elizabeth Fox, Carlos Rodriguez-Galindo, Brigitte C. Widemann, O Morgan Hall, AeRang Kim, Emily Stern, Rochelle Bagatell, Nalini Jayaprakash, Jeffrey S. Dome, Pamela S. Hinds, Jane E. Minturn, Tristan M. Sissung
Publikováno v:
Pediatric Blood & Cancer. 68
Background Sorafenib,an orally bioavailable, multitarget tyrosine kinase inhibitor, and irinotecan, a topoisomerase I inhibitor, have demonstrated activity in pediatric and adult malignancies. We evaluated the toxicity, pharmacokinetic (PK), and phar
Autor:
Rachael F. Grace, Clement Ma, Wendy B. London, Cindy Neunert, Ellis J. Neufeld, Carolyn M. Bennett, Kristin A. Shimano, Jenny M. Despotovic, Robert J. Klaassen
Publikováno v:
BMJ open, vol 11, iss 8
BMJ Open
BMJ Open, Vol 11, Iss 8 (2021)
BMJ Open
BMJ Open, Vol 11, Iss 8 (2021)
IntroductionImmune thrombocytopaenia (ITP) is an acquired disorder of low platelets and risk of bleeding. Although many children can be observed until spontaneous remission, others require treatment due to bleeding or impact on health-related quality
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ada1f7f32838d70bd65160fbd94c2a48
https://escholarship.org/uc/item/9h11s5hj
https://escholarship.org/uc/item/9h11s5hj
Autor:
Emily Hibbitts, Julie R. Park, M. Meaghan Granger, Rochelle Bagatell, Navin Pinto, Susan G. Kreissman, Meredith S. Irwin, Wendy B. London, Arlene Naranjo, Emily Greengard, Steven G. DuBois
Publikováno v:
Eur J Cancer
Induction chemotherapy plays an important role in the management of patients with high-risk neuroblastoma. Predictors of response to induction therapy are largely lacking. We sought to describe clinical and biological features associated with inducti
Autor:
Sheena C. Tenney, Mary Lou Schmidt, John M. Maris, Katherine K. Matthay, Clare J. Twist, Wendy B. London, E. Stanton Adkins, Peter Mattei, Susan L. Cohn, Julie R. Park, Holly J. Meany, Hiroyuki Shimada, Arlene Naranjo
Publikováno v:
Journal of Clinical Oncology. 37:115-124
Purpose Infants with stage 4S neuroblastoma usually have favorable outcomes with observation or minimal chemotherapy. However, young infants with symptoms secondary to massive hepatomegaly or with unfavorable tumor biology are at high risk of death.